Arrowhead receives regulatory clearance to begin phase 1 study of ARO-AAT
Arrowhead Pharma announced it has received approval from the New Zealand MEDSAFE and from the local Ethics Committee to proceed with a first-in-human study of ARO-AAT, which is being developed as treatment for a rare genetic liver disease associated with alpha-1 antitrypsin deficiency. February 22, 2018